Abstract
Sirtuin 2 (SIRT2) is a protein lysine deacylase that has been indicated as a therapeutic target for cancer. To further establish the role of SIRT2 in cancers, it is necessary to develop selective and potent inhibitors. Here, we report the facile synthesis of novel lysine-derived thioureas as mechanism-based SIRT2 inhibitors with anticancer activity. Compounds AF8, AF10, and AF12 selectively inhibited SIRT2 with IC50 values of 0.06, 0.15, and 0.08 μM, respectively. Compounds AF8 and AF10 demonstrated broad cytotoxicity amongst cancer cell lines, but minimal toxicity in noncancerous cells. AF8 and AF10 inhibited the anchorage-independent growth of human colorectal cancer cell line HCT116 with GI50 values of ∼7 μM. Furthermore, AF8 potently inhibited tumor growth in a HCT116 xenograft murine model, supporting that SIRT2 is a viable therapeutic target for colorectal cancer.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / metabolism
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Binding Sites
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Colorectal Neoplasms / drug therapy
-
Colorectal Neoplasms / pathology
-
Disease Models, Animal
-
Drug Design
-
Drug Screening Assays, Antitumor
-
Female
-
Humans
-
Lysine / chemistry*
-
Male
-
Mice
-
Mice, Transgenic
-
Molecular Docking Simulation
-
Protein Isoforms / antagonists & inhibitors
-
Protein Isoforms / metabolism
-
Sirtuin 2 / antagonists & inhibitors*
-
Sirtuin 2 / metabolism
-
Structure-Activity Relationship
-
Thiourea / chemical synthesis
-
Thiourea / chemistry*
-
Thiourea / pharmacology
-
Thiourea / therapeutic use
Substances
-
Antineoplastic Agents
-
Protein Isoforms
-
Sirtuin 2
-
Thiourea
-
Lysine